Israel News Roundup – NOVEMBER 2017
November 30, 2017 - 6 minutes readWelcome to Pillar & Cloud’s Israel News Roundup for this month. Below are some interesting articles we came across and wanted to share with our P&C community. BY ARIEL SHAPIRA AppsFlyer recently held its inaugural “All Hands” event, which brought together 300 plus employees from 13 different offices around the globe to its headquarters in Herzliya Pituah. CellSavers, the instant services company for smart devices, has rebranded as Puls and raised $25 million in a new round of funding. The funding round is led by Red Dot Capital Partners – a Temasek Holdings-backed growth fund – with support from new investors Samsung Next, Maverick Ventures and Kreos Capital, along with participation from existing investors Sequoia Capital and Carmel Ventures. With $43m. raised to date, the new funding will empower Puls to widen its current offering of rapid-response, in-home digital services beyond cell phone and tablet repair to span flat screens, security cameras, voice-control and home automation products from any smart device manufacturer. The company is expanding its offering to cover the full life-cycle of a digital device, encompassing in-home demonstration, installation, setup, integration, support, repair, and trade-in. The funding will also be used to expand into new US markets. SOURCE: The Jerusalem Post BY SHARON UDASIN New liquid medication to provide continuous treatment that would be less invasive. One Israeli company may have a billion-dollar solution to making treatment regimens more convenient and effective for patients with advanced Parkinson’s disease. Just two weeks ago, the Rehovot-based NeuroDerm announced that it had entered a definitive agreement to be acquired by the Japanese company Mitsubishi Tanabe Pharma for $1.1 billion. While NeuroDerm has a number of technologies in its pipeline, the particular product that attracted the Japanese investment was ND0612 – a liquid medication still under clinical trials that could provide patients with a continuous, less invasive treatment option. We have been able to produce a liquid formulation for the first time that can be administered inside the body directly, not through the stomach, but under the skin,” Dr. Sheila Oren, NeuroDerm’s chief medical officer, told The Jerusalem Post on Sunday. Oren has two decades of international pharmaceuticals experience and has been responsible for the clinical development and marketing of several central nervous system drugs. As chief medical officer at NeuroDerm, she has been overseeing the development of ND0612 and several other medicines that could potentially provide life-changing opportunities to patients. In patients who suffer from Parkinson’s disease, certain brain cells begin to die and therefore stop producing dopamine, a chemical that is critical to movement, Oren explained. To compensate for that loss of dopamine, replacement therapy through a drug called levodopa, or L-dopa, has thus far been the best treatment option, she said. SOURCE: The Jerusalem Post BY ISRAEL Agriculture Technology SOURCE: Youtube I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.2. TECH TALK: BUILDING FOR BETTER AND QUICKER DIGITAL
3. A LOOK AT THE $1.1B. ISRAELI TECHNOLOGY FOR REGULATING PARKINSON’S
5. Amazing agriculture technology: Desert Agriculture technology in ISRAEL
